Therapeutic Class

Equine Rhinopneumonitis and Influenza Vaccine

A combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Equine Herpesvirus EHV-1 and EHV-4 and Equine Influenza Virus subtype A2 including KY 93, KY02, and NM2/93 strains. Merck Animal Health serological data suggest cross protection against certain U.S. and European strains, including Kentucky 91, 93, 99, 02, Ohio 03, Newmarket 1/93, Newmarket 2.93, Suffolk 89, and South Africa 03.

For vaccination of healthy horses, 6 months of age or older, as an aid in the control of respiratory disease caused by Equine Influenza Virus and Equine Herpesvirus and as an aid in the reduction of Influenza virus shedding. Duration of Immunity (DOI) has been shown to be at least 6 months for Influenza. Foals nursing immune-dams should be vaccinated when maternal antibody levels will allow active immunization.

Administration and Dosage

For primary immunization, aseptically inject 1 mL intramuscularly. Repeat the dose in 3 to 4 weeks. Annual revaccination is recommended. A booster dose can be administered at more frequent intervals based upon individual horse or farm disease risk assessment or any time epidemic conditions exist or are reported. Consult your veterinarian.

Store at 35o to 45oF (2o to 7oC). Shake well before using. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

Epinephrine. Neomycin, polymyxin B, nystatin and thimerosal added as preservatives.

Code: 030791
10 X 1 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.
Code: 030872
10 mL (10 doses) vial.

Product Label(s) and MSDS

For more information about Merck Animal Health Products call 1-800-441-8272.